SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MEDX ... anybody following?
MEDX 31.58+1.4%Nov 5 12:44 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Icebrg11/2/2007 4:06:41 AM
   of 2240
 
Table 1. Final Rankings of Agents with High Potential for Use in Treating Cancer

Source: NCI Immunotherapy Agent Workshop Proceedings (july 2007)

URL: isbtc.org


Rank* Agent                         Agent Category 
1     IL-15                         T-Cell Growth Factor  
2     Anti-Programmed Death-1       **T-Cell Checkpoint Blockade Inhibitor 
     (PD1)and/or anti–B7-H1 (PD1 
      Ligand)  
3     IL-12                         Vaccine Adjuvant 
4     Anti-CD40 and/or CD40L        Antigen Presenting Cell Stimulator 
5     IL-7                          T-Cell Growth Factor 
6     CpG                           Vaccine Adjuvant 
7     1-Methyl Tryptophan           Enzyme Inhibitor 
8     Anti-CD137 (anti–4-1BB)       T-Cell Stimulator 
9     Anti–TGF-beta                 Signaling Inhibitor 
10    Anti–IL-10 Receptor or Anti–
      IL-10                         Suppression Inhibitor   
11    Flt3L                         Dendritic Cell Growth Factor/Vaccine Adjuvant  
12    Anti-Glucocorticoid-Induced 
      TNF Receptor (GITR)           T-cell Stimulator 
13    CCL21                         Adenovirus  T-Cell Attracting Chemokine 
14    Monophosphoryl Lipid A (MPL)  Vaccine Adjuvant 
15    Poly I:C and/or Poly ICLC     Vaccine Adjuvant 
16    Anti-OX40                     T-Cell Stimulator 
17    Anti–B7-H4                    T-Cell Checkpoint Blockade Inhibitor 
18    Resiquimod and/or 852A        Vaccine Adjuvant 
19    LIGHT and/or LIGHT vector     T-Cell Stimulator 
20    Anti–Lymphocyte Activation 
      Gene-3 (LAG-3)                T-Cell Checkpoint Blockade Inhibitor

*Final rank was derived from voting by the workshop participants. The agents are listed according to median rankings. Means were used to break ties (see Table 4 for details).

**Anti-CTLA-4, a T-cell checkpoint blockade inhibitor, was considered of exceedingly high value but was not included on the list, as it is being produced by Bristol-Myers Squibb and Pfizer and is likely to be approved by the FDA within the foreseeable future.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News